在肝细胞癌中评估转录组分子分类、生物学行为和临床病理学特征。
Evaluation of transcriptomic molecular classification, biological behavior, and clinicopathological features in hepatocellular carcinoma.
发表日期:2023 Feb 01
作者:
Ruonan Chen, Zixiong Zhou, Yi Chen, Aimin Huang, Lihong Chen
来源:
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
摘要:
在法国、韩国和新加坡的研究中发现G1-G6转录组与肝细胞癌(HCC)的致癌有关。然而,该方法在中国HCC患者中的适用性仍然未知。通过回顾性队列研究,分析了107名中国HCC患者G1-G6分子分类与临床病理特征之间的相关性。进行RNA测序和生物信息学分析,筛选相关的靶点和分子信号通路。我们发现,G1-G3亚组与高血清α-胎蛋白(AFP)水平、乙型肝炎病毒(HBV)DNA复制数、复杂的组织学结构、大血管浸润有关。G1亚组主要与肝癌干细胞相关,G3亚组显示出最糟糕的预后。G5和G6亚组与Wnt/β-连环蛋白途径的激活有关。与G4-G6组相比,G1-G3组显示出再生家族成员1β(REG1B)、再生家族成员3γ(REG3G)和肌醇1,4,5-三磷酸受体1(ITPR1)的显著高表达水平,并富集了钙信号通路。本研究加深了我们对中国HCC异质性的理解,并表明G1-G6标记可以用于识别中国HCC患者的预测性生物标志物。
Studies in France, Korea, and Singapore found that G1-G6 transcriptomes are involved in hepatocellular carcinoma (HCC) carcinogenesis. However, the suitability of this method in Chinese HCC patients has remained unknown.The correlation between the G1-G6 molecular classification and clinicopathological features were analyzed in 107 Chinese HCC patients through the retrospective cohort study. RNA sequencing and bioinformatics analysis were performed to screen related targets and molecular signaling pathways.We found that the G1-G3 subgroups were associated with high serum alpha-fetoprotein (AFP) level, high copy number of hepatitis B virus (HBV) DNA, complex histopathological structure, macrovascular invasion. The G1 subgroup was mainly related to liver cancer stemness, and G3 subgroup showed the worst prognosis. The G5 and G6 subgroups were associated with activation of the Wnt/β-catenin pathway. Compared with the G4-G6 group, the G1-G3 group showed significantly higher expression levels of regenerating family member 1 beta (REG1B), regenerating family member 3 gamma (REG3G), and inositol 1,4,5-trisphosphate receptor type 1 (ITPR1), and enriched calcium signaling pathway.This study enhances our understanding of the heterogenicity of China HCC and indicates that the G1-G6 signatures can be used to identify predictive biomarkers against HCC patients in China.